Страна: Новая Зеландия
Язык: английский
Источник: Medsafe (Medicines Safety Authority)
Enalapril maleate 10mg;
Multichem NZ Limited
Enalapril maleate 10 mg
10 mg
Tablet
Active: Enalapril maleate 10mg Excipient: Hypromellose Iron oxide red Lactose Maize starch Purified talc Stearic acid
Bottle, plastic, HDPE with silica gel canister, 90 tablets
Prescription
Prescription
Neuland Laboratories Limited
All grades of essential hypertension.
Package - Contents - Shelf Life: Bottle, plastic, HDPE with silica gel canister - 90 tablets - 36 months from date of manufacture stored at or below 25°C protect from light
2001-02-07
M-ENALAPRIL ENALAPRIL MALEATE 5 MG, 10 MG, AND 20 MG TABLETS USP PRESENTATION 5 mg tablet: A white, round, flat-faced with bevelled edge tablet. The tablet is debossed W over 924 on one side with a break line on the other. Each tablet contains 5 mg of enalapril maleate. 10 mg tablet: A light salmon coloured, round, flat-faced with bevelled edge tablet. The tablet is debossed W over 925 on one side and plain on the other side. Each tablet contains 10 mg of enalapril maleate. 20 mg tablet: A light beige coloured, round, flat-faced with bevelled edge tablet. The tablet is debossed W over 926 on one side and plain on the other side. Each tablet contains 20 mg of enalapril maleate. THERAPEUTIC CLASS m-Enalapril (enalapril maleate) is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-prolin. Following oral administration, enalapril is rapidly absorbed and then hydrolysed to enalaprilat, which is a highly specific, long acting, non-sulphydryl angiotensin converting enzyme inhibitor. INDICATIONS Treatment of: All grades of essential hypertension Renovascular hypertension All degrees of heart failure In patients with symptomatic heart failure, m-Enalapril is also indicated to: Improve survival Retard the progression of heart failure Reduce hospitalisation for heart failure Prevention of symptomatic heart failure In asymptomatic patients with left ventricular dysfunction, m-Enalapril is indicated to: Retard the development of symptomatic heart failure Reduce hospitalisation for heart failure Prevention of coronary ischaemic events in patients with left ventricular dysfunction m-Enalapril is indicated to: Reduce the incidence of myocardial infarction Reduce hospitalisation for unstable angina pectoris DOSAGE AND ADMINISTRATION Since absorption of enalapril maleate tablets is not affec Прочитать полный документ